跳至主要内容
临床试验/NCT02130167
NCT02130167
已完成
不适用

Low Concentrations of Atropine for Controlling Myopia Progression in School Children

Chang Gung Memorial Hospital1 个研究点 分布在 1 个国家目标入组 60 人2012年8月
干预措施Atropine
相关药物Atropine

概览

阶段
不适用
干预措施
Atropine
疾病 / 适应症
Myopia Progression
发起方
Chang Gung Memorial Hospital
入组人数
60
试验地点
1
主要终点
Cycloplegic spherical refraction change
状态
已完成
最后更新
8年前

概览

简要总结

Myopia is the leading cause of blindness in Taiwan. The younger children with myopia, the higher risk of high myopia in later life and complications such as retinal detachment and maculopathy will occur. We have reported the low concentration of atropine (0.05%) with the effect on retarding the myopia progression. Recently the 0.01% atropine was also reported effective and with less visual side effects such as mydriasis. The aim of this study is to compare the efficacy in controlling myopia progression and visual side effects of 2 low concentration of atropine(0.05% vs 0.01%) in children aged 6-12 years with myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

注册库
clinicaltrials.gov
开始日期
2012年8月
结束日期
2017年8月
最后更新
8年前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

发起方
Chang Gung Memorial Hospital
责任方
Sponsor

入排标准

入选标准

  • Myopia of at least -0.5 diopters (D) and astigmatism of -1.50 D or less.

排除标准

  • strabismus, amblyopia. cataract, glaucoma or any ocular diseases ocular surgery history systemic diseases (ex. asthma, heart disease...)

研究组 & 干预措施

0.01% Atropine

干预措施: Atropine

0.05% Atropine

干预措施: Atropine

结局指标

主要结局

Cycloplegic spherical refraction change

时间窗: 1 year

Cycloplegic spherical refraction change is the main indicator of the myopia progression.

次要结局

  • Axial length change(1 year)

研究点 (1)

Loading locations...

相似试验